Cadenza Bio
Life Sciences
Cadenza Bio is dedicated to breaking the cycle of MS, leading to transformative changes in patient lives. This goal extends beyond symptom relief; they strive to halt the progression of disease and return high quality of life to patients.
Why we invested:
Superior Technology
Cadenza Bio was founded to accelerate and support the development of a series of novel, non-steroidal, highly selective compounds targeting Estrogen Receptor â (ERâ). Its patented and patent-pending compounds have shown therapeutic efficacy in preclinical animal models of MS and Endometriosis.
Founders & Team
Founder/CEO Carol Curtis, PhD has strong expertise in company building, early-stage venture capital, managing operations and R&D, and interacting with FDA. Founder/COO Elaine Hamm, PhD has extensive experience in drug development and technology transfer and has successfully exited two portfolio companies.
-
"We could not be more pleased to have Boyd Street Ventures as an investor. Their management team and Strategic Advisory Board can be a great source of insight, particularly in the areas of strategy and operations, and they are actively engaged in the honing for success."
Jesse McCool Co-Founder & CEO, Wheeler Bio -
"James has been extremely helpful in making important introductions for us. I appreciate the fact that he’s always asking me about our plans to grow even faster, and it seems that every time I talk to him he has another great idea for a potential new customer."
Nathan Den Herder Founder & CEO, Ardley